Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
November 14, 2022 06:00 ET
|
Lumos Pharma, Inc.
- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - - Interim...
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
September 26, 2022 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2022 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials...
Lumos Pharma Announces Share Repurchase Program
August 16, 2022 07:30 ET
|
Lumos Pharma, Inc.
-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing...
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
August 09, 2022 16:01 ET
|
Lumos Pharma, Inc.
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24...
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
July 27, 2022 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial...
Lumos Pharma to Participate in Upcoming Investor Conferences
May 16, 2022 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
May 10, 2022 16:01 ET
|
Lumos Pharma, Inc.
--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12...
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
May 05, 2022 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric...
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
April 26, 2022 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results...